Intermittent claudication is the most common symptom of peripheral arterial disease (PAD), in part due to an inadequate rise in limb blood flow with exercise. Claudication causes a severe impairment in functional capacity and quality of life in over 3 million Americans. Basic fibroblast growth factor (bFGF) stimulates angiogenesis in vivo and improves limb blood flow in several animal models of hindlimb ischemia. However, the relative safety and efficacy of angiogenic molecules in the treatment of claudication has not been fully evaluated in prospective, blinded clinical trials. In this study, a randomized, double-blind, placebo-controlled, phase II trial of recombinant human bFGF for the treatment of intermittent claudication was performed. bFGF was administered weekly by intravenous infusions of 2 g/kg for 6 sequential weeks (total dose 12 g/kg). The primary efficacy endpoint was change in peak walking time (PWT) on a graded exercise treadmill protocol. Secondary efficacy endpoints included changes in functional status as measured by validated questionnaires. The study was stopped prematurely after treatment of the first 24 subjects due to proteinuria in five of the 16 subjects who received systemic bFGF, which exceeded 1000 mg/24 h in four of these five subjects. The small sample size limited evaluation of the predefined efficacy endpoints; however, there was no significant difference between the treatment and control groups for any of the measures of efficacy. In conclusion, intravenous administration of bFGF delivered at low doses weekly for 6 weeks was associated with a high rate of severe proteinuria. It is speculated that bFGF-related proteinuria in this study was primarily related to the systemic route of administration and the frequent dosing schedule. Future clinical trials of bFGF protein should carefully monitor renal function and consider alternative dosing schedules and drug administration routes. Alan T Hirsch (3); Brigham and Women's Hospital, Boston, MA -Mark A Creager (2); Mayo Clinic and Foundation, Cardiovascular Division, Rochester, MN -Leslie T Vascular Medicine 2001; 6: [235][236][237][238][239] Cooper, Jr (2); University of Texas at Houston, TX -Ward Casscells (1).
Introduction
Atherosclerotic peripheral arterial disease (PAD) is present in approximately 11-25% of the population over the age of 60 years. 1, 2 The most common symptom of PAD is intermittent claudication (IC), which affects over 3 million Americans. Therapies to improve claudication symptoms include the use of supervised walking programs, pharmacotherapies (e.g. cilostazol 3 and pentoxifylline 4 ), and selective use of revascularization. Agents under investigation include Ginko biloba, 5 carnitine, 6 and l-arginine. 7 Risk factor modification and antiplatelet therapies can prevent cardiovascular ischemic events. 8, 9 Despite such therapeutic interventions, most patients with claudication suffer persistent functional limitations and a diminished quality of life. [10] [11] [12] Basic fibroblast growth factor (bFGF) is a 154 amino acid polypeptide that stimulates angiogenesis in vivo. 13 Preclinical studies in rabbits and rats with hindlimb ischemia demonstrated that bFGF administered via a variety of routes resulted in improved total blood flow, oxygen delivery, capillary density, and ischemic limb function. 14 These preclinical data suggest that bFGF may provide a future therapeutic avenue to potentially improve claudication due to PAD. We hypothesized that bFGF would improve peak walking distance as compared to placebo in patients with intermittent claudication.
Methods

Study design
The study was a randomized, 2:1 treatment:placebo, double-blind, multicenter, dose-escalation evaluation of intravenous Fiblast (bFGF; Scios, Mountain View, CA, USA) with patients enrolled between 28 Jan 1997 and 5 August 1997. Although a sample size of 108 subjects was to be enrolled to permit efficacy analyses, the study was terminated prematurely after treatment of the initial 24 subjects because of development of severe proteinuria in the treatment group. Treatment subjects (n = 16) received a total dose of 12 g/kg of recombinant human bFGF (Fiblast) in six weekly 4-h intravenous infusions of 2 g/kg. Planned dose escalation was not achieved because the study was terminated prematurely.
The major inclusion criteria for study participation were: male or female subject at least 18 years of age; PAD documented by an ankle-brachial index (ABI) less than 0.90 at rest, with a decrease in ABI of greater than 20% after exercise; initial maximal exercise time of 1-12 min on a screening exercise test; and the ability to provide written, informed consent. Major exclusion criteria included: the presence of ischemic rest pain or skin ulceration; nonatherosclerotic PAD such as vasculitis; any history or current evidence of malignancy; and proliferative retinopathy. Patients were also excluded from study participation if they had any baseline renal disease, defined as a blood urea nitrogen greater than 35 ng/dl, creatinine greater than 2.0 mg/dl, or greater than 250 mg protein per 24-h urine collection.
Efficacy evaluation
The primary efficacy endpoint was designed to be the peak walking time on a graded exercise treadmill protocol evaluated at weeks 4, 8 and 12. 15 Secondary efficacy endpoints included a quality of life assessment by medical outcomes study SF-36 and the walking impairment Questionnaire. 16 
Safety evaluation
During study drug infusion, vital signs were obtained at baseline and hourly for 4 h. Physical examinations, interim medical histories, and a battery of laboratory studies with special attention to blood and urine markers of renal function were obtained weekly during study weeks 2 through 8. A Data and Safety Monitoring Committee (DSMC) consisting of independent experts in cardiovascular disease and research (members listed in 'Acknowledgements') assisted in monitoring safety issues during the trial. A formal review by the DSMC was requested when the number of serious adverse events in the bFGF group exceeded that in the placebo group by three.
Statistical methods
All subjects who received treatment and from whom data were collected were analyzed according to the treatment that they actually received. The two treatment groups were compared using the two-sample t-test with Satterthwaite's approximation to the degrees of freedom or the two-sample Wilcoxon test. Within-group changes from baseline were tested with either a paired t-test or one-sample Wilcoxon test. For adverse events, the proportion of subjects reporting an adverse event was compared using Fischer's exact test. All reported p-values are two-sided with pϽ0.05 considered statistically significant. No overall adjustment of alpha levels was attempted.
This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki. The protocol and informed consent forms were approved by institutional review boards at each participating institution. All patients offered written informed consent.
Results
A total of 24 subjects was enrolled at seven centers in the USA, including 16 men (67%) and eight women (33%). The cohort age, gender mix, atherosclerosis risk factors, creatinine, and baseline ABI were not different in these small treatment groups (Table 1) . Two subjects dropped out during the study: one in the placebo group withdrew consent and was lost to follow-up after week 5 and one bFGF patient died following complications of coronary artery bypass surgery 107 days after the last dose of study drug. These subjects are included in all analyses for which there were data. Sixteen subjects received the active drug and eight received the placebo. Of the 16 subjects treated with bFGF, 13 received all six doses, and three received five doses. In general, protocol deviations were minor, with the exception that one subject with proteinuria (704 mg/24 h) at baseline was randomized in the treatment group.
The treadmill exercise data are displayed in Table 2 . The time to onset of claudication and total walking time were not significantly different in the bFGF and placebo groups. Although the placebo group appeared to have a lower mean treadmill claudication time at baseline, this was due to a few extreme values in the bFGF group. There was no significant improvement in the primary efficacy endpoint of total walking time on a graded exercise treadmill at weeks 4, 8, or 12. There was also no significant improvement in the secondary endpoint, the time to onset of claudication at weeks 4, 8, or 12 (Table 2 ), in the pre-and post-exercise ABI, or in any of the quality of life scores as measured by the SF-36 and the Walking Impairment Questionnaire.
The adverse event profile in this phase II study is depicted in Table 3 . Severe proteinuria (greater than 1 g/24 h) was the most significant and frequently reported single adverse event in the bFGF-treated group (occurring in 4/16 of the bFGF-treated patients versus in 1/8 of the placebo-treated patients). Hypertension worsened in 2/16 bFGF-treated patients. Gastrointestinal disturbances also occurred more frequently in the bFGF group, including nausea (19% versus 0%), loss of appetite (6% versus 0%), and diarrhea (13% versus 0%). One subject in the FGF group died at day 107 of multiorgan system failure after coronary artery bypass surgery. This death was considered to be unrelated to the study drug. Other than proteinuria, no other clinically significant hematology or chemistry laboratory abnormalities were observed.
Four subjects in the bFGF group with normal renal function as assessed by BUN and creatinine at baseline developed marked quantitative proteinuria (greater than 1 g/24 h). The peak urine protein levels during study weeks All data presented as mean ± SD. In three subjects, the proteinuria reversed after drug discontinuation. The fourth patient continued to have proteinuria through the end of study follow-up despite discontinuing treatment. A fifth patient had an increase in qualitative proteinuria, from trace to 1+ during FGF treatment. Quantitative urine protein was not obtained in this subject. One patient in the placebo group developed proteinuria (678 mg/24 h at week 5. Although proteinuria was not associated with any pretreatment clinical, hematologic, or chemistry values (e.g. BUN, creatinine, serum or urine protein), the small sample size precludes identification of specific risk factors for bFGF-related proteinuria. The time course of this proteinuria is depicted in Figure 1 . 
Discussion
Phase II clinical trials are designed in order to begin a careful, deliberate definition of drug safety and efficacy in a population of patients representative of those who might receive the pharmacologic agent in either subsequent phase III studies or in community practice. This phase II evaluation of a promising angiogenic protein, delivered by repeated systemic infusion, was associated with significant renal toxicity. Because the study was stopped early, neither the intended sample size nor the intended bFGF dose were attained. Therefore, the efficacy of bFGF for the treatment of intermittent claudication could not be assessed in the context of this protocol. However, this renal toxicity provides insight that might prove very helpful to the future design of subsequent angiogenesis clinical trials for patients with PAD and/or other unrelated disorders. Preclinical studies indicated that the kidney, which makes and stores bFGF, could be a target organ for bFGF toxicity. 17 Proteinuria was observed in cynomolgus monkeys and rats who received 4 weeks of treatment with bFGF administered intravenously at 10 and 100 g/kg per day (monkey), and at 100 g/kg per day (rat). The rat glomerulus developed enlargement and vacuolization of podocytes with loss of foot processes starting at day 16. Glomeruli in all parts of the cortex were affected. In the monkey, the lesions were hyperplasia of the parietal epithelium of Bowman's capsule. Although proteinuria occurred in both species, the bFGF doses were 35-to 350-fold higher than was used in our clinical study. We note that inter-species and age-related differences in drug metabolism can be striking, and dose-response relationships may shift when the drug is subsequently studied in humans.
Two clinical studies of bFGF (Fiblast) report proteinuria data. In an NIH-sponsored phase I, randomized, dose-escalation trial, bFGF (Fiblast) was administered as an intraarterial infusion in 19 subjects with intermittent claudication due to PAD. Quantitative urine proteinuria was less than 200 mg/day at baseline in all subjects. Transient mild proteinuria occurred in half of the subjects who received the placebo and in almost half of those who received the active study drug. 18 In a second NIH-sponsored phase I, randomized, dose-escalation trial, in which bFGF (Fiblast) was administered as an intracoronary injection for coronary heart disease (CAD), the placebo and treatment groups had similar rates of transient mild proteinuria. 19 Another bFGF which differs from Fiblast by two amino acids was studied in two clinical trials in patients with CAD 20,21 : a phase I, open-label, dose escalation study in 66 subjects with severe CAD and a phase II, double-blind, placebo-controlled study in 337 subjects with severe CAD. In the phase I trial, patients were excluded if their creatinine clearance was Ͻ80 ml/min or quantitative protein was Ͼ200 mg/day. Doses studied ranged from 0.33 g/kg to 48.0 g/kg administered as a single infusion by the intracoronary or intravenous route; 46/66 subjects received doses of 12 g/kg or greater. Transient proteinuria (Ͼ300 mg/day) was seen in 3/66 subjects and was not dose related. In the phase II trial, patients were excluded for serum creatinine Ͼ2.0 mg/dl or Ͼ trace proteinuria on urinalysis. Doses studied included 0.3, 3.0, and 30.0 g/kg administered as a single intracoronary infusion. Proteinuria (Ͼ300 mg/day) was seen in 7/337 subjects and was not dose related.
In summary, bFGF administered intravenously in subtherapeutic doses of 2 g/kg per week for 6 weeks is associated with a high rate of proteinuria in humans. Based on preclinical data, the mechanism of toxicity is probably due to structural changes in the glomerulus, and not a direct angiogenic effect. We conclude that the route and dose regimen in our trial should not be used in further clinical studies. growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000; 36(7): 2132-39.
